Tenax Therapeutics (TENX) Financials

Tenax Therapeutics’ latest quarter shows a company still in development mode, with no revenue, continuing operating losses, and a balance sheet that is now much larger and more liquid than it was a year ago. The biggest takeaway for retail investors is that TENX has raised substantial capital and is sitting on a large cash balance, but it is also burning that cash quickly to fund research and operations.

• Cash increased sharply. Tenax ended Q1 2026 with $118.8 million in cash and equivalents, up from $99.4 million at the end of Q3 2025 and far above the sub-$15 million level seen in early 2024.
• Liquidity remains strong relative to liabilities. Total current assets of $123.2 million versus total current liabilities of $8.5 million leaves the company with a very large current ratio and plenty of near-term flexibility.
• No debt on the balance sheet in Q1 2026. Reported short-term and long-term debt were both $0, reducing balance sheet risk.
• Equity base improved materially. Total common equity rose to $114.7 million, reflecting the impact of financing activity and capital raises.
• Operating cash outflow improved year over year. Net cash used in operating activities was $9.3 million in Q1 2026, better than the $13.4 million used in Q4 2025 and roughly in line with the company’s recent burn profile.
• R&D spending remains high. Research and development expense was $11.5 million in Q1 2026, indicating continued investment in the pipeline, but also a significant cash requirement.
• Interest and investment income helps offset losses. The company earned $861,000 in interest and investment income in Q1 2026, which slightly reduces the pre-tax loss.
• There is still no revenue. Tenax reported $0 in revenue in Q1 2026, so the business remains entirely dependent on future clinical and regulatory success.
• Losses continue at a meaningful pace. Net loss was $15.7 million in Q1 2026, or -$0.35 per share.
• Share dilution has been significant over the past year. Weighted average basic shares rose from about 365.8 million in Q1 2025 to 452.3 million in Q1 2026, suggesting meaningful dilution from financing activity.

Looking at the broader trend over the last four years, Tenax has moved from a very small cash balance and modest equity base in early 2024 to a much better-funded position today. That is a clear positive for survivability. However, the company has not yet shown an ability to generate sales, and operating losses remain substantial.

One notable positive is that the company’s cash position has grown faster than its quarterly operating burn, largely because of financing inflows. In Q1 2026, financing activities added $30.5 million in cash, which more than offset operating outflows. That means the balance sheet currently looks much stronger than the income statement.

For investors, the key question is not near-term solvency, but whether Tenax can translate its research spending into a commercial or clinical catalyst before the cash pile is meaningfully eroded. Until revenue appears, the stock will likely trade primarily on clinical progress, capital markets access, and dilution risk.